The Arkansas Integrative Metabolic Research Center will explore the potential of a novel, artificially designed, hybrid growth factor to regulate the metabolism of fat and cancer cells.

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Strongrevenueperformance,includingapproximately$1.9millionmilestoneandlicenserevenuerecognizedin2024Up to $7.5 million in grants awarded from ...

For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne ...

Q4 2024 Earnings Call Transcript March 26, 2025 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $ ...

Equities research analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for shares of Tyra Biosciences in a research report issued on Friday, March 28th. Wedbush analyst R.

Wedbush reiterated their outperform rating on shares of Tyra Biosciences (NASDAQ:TYRA – Free Report) in a report issued on Friday,RTT News reports. The firm currently has a $30.00 price objective on ...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized ... Growth Factors: Dyadic is advancing the development of recombinant Fibroblast Growth ...